The Phase 2 LOTUS data positions abdakibart as a potential best-in-class HS therapy, and the $431M financing removes near-term dilution risk. Traders should watch for Phase 3 trial initiation and potential partnership interest. The EPS miss is immaterial for a pre-revenue biotech; the clinical and financing catalysts dominate.
Price Chart
Executive Summary
Avalo Therapeutics reported Q1 2026 EPS of -$0.98, missing the -$1.01 consensus by 3.0% (a miss), with no revenue. The headline miss is overshadowed by transformative pipeline progress: positive Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa (HS) and a $431.3M public offering completed post-quarter, extending cash runway into 2029. The stock will move on the clinical catalyst and financing strength, not the GAAP earnings miss.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.98 vs consensus -$1.01 (miss by 3.0%)
- No revenue reported; net loss of $19.6M vs $13.1M in Q1 2025
- Phase 2 LOTUS trial met primary endpoint: HiSCR75 at Week 16 (p=0.004 combined), with 42.5% absolute improvement vs 25.6% placebo
- Completed $431.3M public offering on May 7, 2026; net proceeds ~$405M
- Cash, equivalents, and short-term investments of $82M as of March 31, 2026; pro forma cash expected to fund operations into 2029
- Entered milestone buyout option agreement for abdakibart Phase 3 milestone, reducing potential cash obligation
Financial Impact
EPS miss of $0.03 per share; $431.3M gross offering proceeds provide multi-year runway
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results
- Dilution from the $431M offering will pressure share price in the near term
- Competitive landscape in HS includes approved therapies (Humira, Cosentyx) and other IL-1β programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293838 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access